Moderna partners with nonprofit to use mRNA to address global health challengesnews2022-04-07T12:19:08+00:00April 7th, 2022|FierceBiotech|
Pfizer nabs RSV therapeutic biotech ReViral in quick $525M bolt-onnews2022-04-07T11:53:12+00:00April 7th, 2022|FierceBiotech|
ArkBio’s ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more datanews2022-04-07T10:25:03+00:00April 7th, 2022|FierceBiotech|
AstraZeneca bets $25M on preclinical bispecific against hot target, docking in Chinese Harbour to land global rightsnews2022-04-07T09:20:35+00:00April 7th, 2022|FierceBiotech|
Gilead unveils pediatric drug development center in Ireland with 33 new jobsnews2022-04-06T18:06:45+00:00April 6th, 2022|FierceBiotech|
Athira board spares no punches to fend off proxy fight from ally of ousted CEOnews2022-04-06T14:15:37+00:00April 6th, 2022|FierceBiotech|
Path cleared for Iovance’s lead melanoma drug after FDA assay feedbacknews2022-04-06T14:01:23+00:00April 6th, 2022|FierceBiotech|
20 years in, Genentech persists and perseveres in Alzheimer’s with gantenerumabnews2022-04-06T13:07:35+00:00April 6th, 2022|FierceBiotech|
Belite Bio hits go on IPO to fund late-phase vision loss clinical trialsnews2022-04-06T12:23:12+00:00April 6th, 2022|FierceBiotech|
FDA oncology chief aims to open up accelerated approval for earlier cancer treatment under ‘Project FrontRunner’news2022-04-06T11:57:22+00:00April 6th, 2022|FierceBiotech|
